as 11-21-2024 4:00pm EST
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Founded: | 2012 | Country: | United States |
Employees: | N/A | City: | EMERYVILLE |
Market Cap: | 459.1M | IPO Year: | N/A |
Target Price: | $9.00 | AVG Volume (30 days): | 509.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.62 | EPS Growth: | N/A |
52 Week Low/High: | $3.56 - $6.72 | Next Earning Date: | 11-12-2024 |
Revenue: | $20,409,000 | Revenue Growth: | -68.45% |
Revenue Growth (this year): | -6.99% | Revenue Growth (next year): | 71.78% |
OABI Breaking Stock News: Dive into OABI Ticker-Specific Updates for Smart Investing
Simply Wall St.
7 days ago
GuruFocus.com
9 days ago
Zacks
9 days ago
Business Wire
9 days ago
GuruFocus.com
11 days ago
Business Wire
23 days ago
Simply Wall St.
a month ago
Business Wire
a month ago
The information presented on this page, "OABI OmniAb Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.